PHARBACO – For the health of Vietnamese people

Pharbaco started out as an enterprise specializing in providing medicine to serve the army during the resistance period and key national health programs.

1. General introduction

• The predecessor of Central Pharmaceutical Joint Stock Company I – Pharbaco was Central Pharmaceutical Enterprise 1, established in 1954 in Hanoi.
• Despite many changes, in 2007, Pharbaco officially implemented its policy of equitization and transformed into its current name.

2. Research and production activities

• Currently owns 3 factories meeting WHO-GMP with a variety of production lines such as antibiotics (oral, injectable), medicinal herbs, traditional medicines, narcotic drugs, psychotropic drugs, and toxic drugs, etc.
• Has a portfolio of more than 500 products with some outstanding products: Sam Nhung bo than trung uong 1, Phabalysin 200 CAP, Enezol 250…
• In 2024, the Company is planning to focus on developing a pharmaceutical factory that meets EU – GMP certification.

3. Business activities

• In 2022, total assets recorded are 2,897 billion VND (short-term assets are 935 million VND and long-term assets are 1,961 billion VND, net revenue reaches 1,057 billion VND, profit after tax is more than 60 billion VND.
• Pharbaco aims to become a complex with all basic production areas in the pharmaceutical industry demonstrated through a series of projects:
  • Invest in building 2 laboratories meeting international standards, 2 product research and development laboratories located in Hanoi and Ho Chi Minh City
  • Continuously strengthen the team of experts and research cooperation with domestic research institutes and universities.